Skip to main content
Top
Gepubliceerd in: Bijblijven 3/2013

01-03-2013 | Artikelen

Late effecten van adjuvante behandeling voor een mammacarcinoom: survivorship care

Auteur: Prof. dr. J.A. Gietema

Gepubliceerd in: Bijblijven | Uitgave 3/2013

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

Veel nadelige effecten van behandelingen van borstkanker treden pas laat op. Voorbeelden hiervan zijn cardiotoxiciteit, ontwikkeling van het metabool syndroom, en osteoporose. Deze late effecten worden mogelijk gunstig beïnvloed of voorkomen, mits tijdig opgespoord. Patiënt en huisarts dienen deelgenoot te worden van de zorg voor deze potentiële late toxiciteit. Dit kan door het ontwikkelen van een duidelijk nazorgplan voor elke overlever, waarin patiënt, huisarts en oncoloog ieder een eigen rol hebben, zogeheten shared care. De huisarts is een belangrijke en logische speler in dit geheel, gezien zijn generalistische achtergrond en zijn kennis van multimorbiditeit. Bij de uitvoering van survivorship care plannen is het van belang een gezonde levensstijl te promoten en te ondersteunen door onder andere patient empowerment. Dit geheel kan bijdragen aan de verwezenlijking van healthy cancer survivorship.
Literatuur
1.
go back to reference Meulepas J, Kiemeney L. Kanker in Nederland tot 2020. Trends en prognoses. Signaleringscommissie Kanker van KWF Kankerbestrijding, 2011. Meulepas J, Kiemeney L. Kanker in Nederland tot 2020. Trends en prognoses. Signaleringscommissie Kanker van KWF Kankerbestrijding, 2011.
2.
go back to reference Ganz PA, Kwan L, Stanton AL, et al. Physical and psychosocial recovery in the year after primary treatment of breast cancer. J Clin Oncol 2011;29: 1101-9.PubMedCrossRef Ganz PA, Kwan L, Stanton AL, et al. Physical and psychosocial recovery in the year after primary treatment of breast cancer. J Clin Oncol 2011;29: 1101-9.PubMedCrossRef
3.
go back to reference Ganz PA, Land SR, Geyer CE, et al. Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. J Clin Oncol 2011;29:1110-6.PubMedCrossRef Ganz PA, Land SR, Geyer CE, et al. Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. J Clin Oncol 2011;29:1110-6.PubMedCrossRef
4.
5.
go back to reference Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. New Engl J Med 2013;368: 987-98.PubMedCrossRef Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. New Engl J Med 2013;368: 987-98.PubMedCrossRef
6.
go back to reference Bowles EJ, Wellman R, Feigelson HS, et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst 2012;104:1293-1305.PubMed Bowles EJ, Wellman R, Feigelson HS, et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst 2012;104:1293-1305.PubMed
7.
go back to reference Khouri MG, Douglas PS, Mackey JR, et al. Cancer therapy-induced cardiac toxicity in breast cancer. Circulation 2012;126:2749.PubMedCrossRef Khouri MG, Douglas PS, Mackey JR, et al. Cancer therapy-induced cardiac toxicity in breast cancer. Circulation 2012;126:2749.PubMedCrossRef
8.
go back to reference Cuppone F, Bria E, Verma S, et al. Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials. Cancer 2008;112:260-7.PubMedCrossRef Cuppone F, Bria E, Verma S, et al. Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials. Cancer 2008;112:260-7.PubMedCrossRef
9.
go back to reference Irwin ML, McTiernan A, Baumgartner RN, et al. Changes in body fat and weight, after a breast cancer diagnosis: influence of demographic, prognostic, and lifestyle factors. J Clin Oncol 2005;23:774-82.PubMedCrossRef Irwin ML, McTiernan A, Baumgartner RN, et al. Changes in body fat and weight, after a breast cancer diagnosis: influence of demographic, prognostic, and lifestyle factors. J Clin Oncol 2005;23:774-82.PubMedCrossRef
10.
go back to reference Jones LW, Courneya KS, Mackey JR, et al. Cardiopulmonary function and age-related decline across the breast cancer survivor continuum. J Clin Oncol 2012 30:2530-7.PubMedCrossRef Jones LW, Courneya KS, Mackey JR, et al. Cardiopulmonary function and age-related decline across the breast cancer survivor continuum. J Clin Oncol 2012 30:2530-7.PubMedCrossRef
11.
go back to reference Haas EC, Oosting SF, Lefrandt JD, et al. The metabolic syndrome in cancer survivors. Lancet Oncology 2010;11: 193-203.PubMedCrossRef Haas EC, Oosting SF, Lefrandt JD, et al. The metabolic syndrome in cancer survivors. Lancet Oncology 2010;11: 193-203.PubMedCrossRef
12.
go back to reference Schaapveld M, Visser O, Louwman MJ, et al. Risk of new primary nonbreast cancers after breastcancer treatment: a Dutch population-based study. J Clin Oncol 2008;26:1239-46.PubMedCrossRef Schaapveld M, Visser O, Louwman MJ, et al. Risk of new primary nonbreast cancers after breastcancer treatment: a Dutch population-based study. J Clin Oncol 2008;26:1239-46.PubMedCrossRef
13.
go back to reference Smith RE, Bryant J, DeCillis A, et al. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer. The NSABP experience. J Clin Oncol 2003;21:1195-1204.PubMedCrossRef Smith RE, Bryant J, DeCillis A, et al. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer. The NSABP experience. J Clin Oncol 2003;21:1195-1204.PubMedCrossRef
14.
go back to reference Jim HS, Phillips KM, Chait S, et al. Meat-analysis of cognitive functioning in breast cancersurvivors previously treated with standard-dose chemotherapy. J Clin Oncol 2012;30: 3578-87.PubMedCrossRef Jim HS, Phillips KM, Chait S, et al. Meat-analysis of cognitive functioning in breast cancersurvivors previously treated with standard-dose chemotherapy. J Clin Oncol 2012;30: 3578-87.PubMedCrossRef
15.
go back to reference Lustberg MB, Reinbolt RE, Shapiro CL. Bone health in adult cancer survivorship. J Clin Oncol 2012;30:3665-74.PubMedCrossRef Lustberg MB, Reinbolt RE, Shapiro CL. Bone health in adult cancer survivorship. J Clin Oncol 2012;30:3665-74.PubMedCrossRef
16.
go back to reference Hewitt M, Greenfield S, Stovall E, et al. From cancer patient to cancer survivor: Lost in transition. Washington DC: National Academies Press, 2006. Hewitt M, Greenfield S, Stovall E, et al. From cancer patient to cancer survivor: Lost in transition. Washington DC: National Academies Press, 2006.
17.
go back to reference Khatcheressioan JL, Hurley P, Bantug E, et al. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology practice guideline update. J Clin Oncol 2012;31:961-5.CrossRef Khatcheressioan JL, Hurley P, Bantug E, et al. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology practice guideline update. J Clin Oncol 2012;31:961-5.CrossRef
18.
go back to reference Snyder CF, Frick KD, Peairs KD, et al. Prevention, screening, and surveillance care for breast cancer survivors compared with controles: changes from 1998 to 2002. J Clin Oncol 2009;27:1054.PubMedCrossRef Snyder CF, Frick KD, Peairs KD, et al. Prevention, screening, and surveillance care for breast cancer survivors compared with controles: changes from 1998 to 2002. J Clin Oncol 2009;27:1054.PubMedCrossRef
19.
go back to reference McCabe MS, Bhatia S, Oeffinger KC, et al. American Society of Clinical Oncology statement: achieving high-quality cancer survivor care. J Clin Oncol 2013;31:631-40.PubMedCrossRef McCabe MS, Bhatia S, Oeffinger KC, et al. American Society of Clinical Oncology statement: achieving high-quality cancer survivor care. J Clin Oncol 2013;31:631-40.PubMedCrossRef
20.
go back to reference Friedenreich CM, Gregory J, Kopciuk KA, et al. Prospective cohort study of lifetime physical activity and breast cancer survival. Int J Cancer 2009; 124:1954-62.PubMedCrossRef Friedenreich CM, Gregory J, Kopciuk KA, et al. Prospective cohort study of lifetime physical activity and breast cancer survival. Int J Cancer 2009; 124:1954-62.PubMedCrossRef
Metagegevens
Titel
Late effecten van adjuvante behandeling voor een mammacarcinoom: survivorship care
Auteur
Prof. dr. J.A. Gietema
Publicatiedatum
01-03-2013
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Bijblijven / Uitgave 3/2013
Print ISSN: 0168-9428
Elektronisch ISSN: 1876-4916
DOI
https://doi.org/10.1007/s12414-013-0037-7

Andere artikelen Uitgave 3/2013

Bijblijven 3/2013 Naar de uitgave